# A Study for Patients With Schizophrenia

> **NCT00520923** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 654 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** LY2140023
- **DRUG:** LY2140023
- **DRUG:** LY2140023
- **DRUG:** LY2140023
- **DRUG:** Olanzapine
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00520923
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2009-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520923, "A Study for Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00520923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*